SAN FRANCISCO, May well 26, 2022 (Globe NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology organization building therapeutics to gradual, halt, or reverse health conditions of getting old, right now announced that Michael Samar, current main economical officer at Assembly Bio, has been appointed to the Company’s board of directors as its chair of the audit committee and a member of its compensation committee.
“We’re thrilled to add Michael to UNITY’s board of directors. With his strong background in biotech finance and operations, mixed with an energetic clean standpoint and track record of execution, Michael’s strategic perspective will be very important as we concentrate on executing on our UBX1325 scientific tests in DME and AMD and offering vital readouts this 12 months,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY Biotechnology.
Mr. Samar at present serves as chief economical officer of Assembly Bio, obtaining been promoted from SVP of finance and small business operations. His prior experience contains serving as Vice President of Finance and Web page Head for the South San Francisco facility at Acorda Therapeutics Director of Monetary Arranging and Examination at Onyx Pharmaceuticals Senior Finance Director, World Planning and Assessment at Agennix, and progressively senior roles in just finance at Johnson & Johnson Pharmaceutical R&D. Mr. Samar obtained his MBA from Villanova University and his BS in finance from Bryant University. He also serves as Treasurer on the Board of OUTbio Bay Region, Inc., a non-financial gain organization for LGBTQ+ experts in the biotech and linked industries.
Concurrent with Mr. Samar’s appointment, Graham K. Cooper has stepped down from the board of administrators.
“Graham has been with UNITY by way of crucial elements of its evolution and has contributed enormously to the Organization, specially as Chair of Audit Committee. On behalf of the entire UNITY group, I would like to thank him for his dedicated service and significant contributions,” mentioned Keith Leonard, chairman of the board of UNITY Biotechnology. “As we head into the vital next 50 percent of 2022, we glimpse forward to doing the job closely with Michael and are delighted to welcome him to our board.”
UNITY is building a new course of therapeutics to slow, halt, or reverse health conditions of growing old. UNITY’s current concentrate is on making medicines to selectively do away with or modulate senescent cells and thus offer transformative advantage in age-related ophthalmologic and neurologic health conditions. Additional data is offered at www.unitybiotechnology.com or observe us on Twitter and LinkedIn.
Forward-On the lookout Statements
This press launch consists of forward-wanting statements which include statements associated to UNITY’s knowledge of cellular senescence and the position it plays in diseases of growing old, the prospective for UNITY to produce therapeutics to sluggish, halt, or reverse conditions of growing old, together with for ophthalmologic and neurologic diseases, the prospective for UNITY to effectively commence and entire medical scientific tests of UBX1325 for DME, AMD, and other ophthalmologic diseases, the predicted timing of enrollment and effects of the scientific trials in UBX1325, and UNITY’s expectations about the sufficiency of its hard cash runway. These statements involve sizeable regarded and not known risks, uncertainties, and other factors that could cause our true outcomes, ranges of activity, efficiency, or achievements to be materially unique from the information and facts expressed or implied by these ahead-wanting statements, such as the threat that the COVID-19 worldwide pandemic may well go on to negatively affect the advancement of preclinical and clinical drug candidates, like delaying or disrupting the enrollment of individuals in clinical trials, risks relating to the uncertainties inherent in the drug development system, and hazards relating to UNITY’s comprehension of senescence biology. We may well not in fact obtain the strategies, intentions, or expectations disclosed in our forward-searching statements, and you must not area undue reliance on our forward-seeking statements. True success or functions could vary materially from the strategies, intentions and anticipations disclosed in the forward-on the lookout statements we make. The forward-hunting statements in this press launch signify our views as of the date of this release. We anticipate that subsequent activities and developments will bring about our views to improve. On the other hand, though we may elect to update these ahead-searching statements at some position in the long term, we have no existing intention of accomplishing so apart from to the extent demanded by applicable law. You really should, as a result, not depend on these ahead-looking statements as symbolizing our views as of any day subsequent to the date of this release. For a further more description of the challenges and uncertainties that could result in true benefits to vary from people expressed in these ahead-looking statements, as well as threats relating to the business enterprise of UNITY in basic, see UNITY’s most current Quarterly Report on Type 10-Q for the quarter ended March 31, 2022, filed with the Securities and Trade Commission on May 10, 2022, as very well as other files that may possibly be submitted by UNITY from time to time with the Securities and Exchange Fee.
Media Get hold of:
Trader Speak to:
Source website link